Form 8-K - Current report:
SEC Accession No. 0001144204-17-058420
Filing Date
2017-11-13
Accepted
2017-11-13 16:53:01
Documents
6
Period of Report
2017-11-07
Items
Item 1.02: Termination of a Material Definitive Agreement
Item 2.04: Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K tv479351_8k.htm 8-K 26692
2 EXHIBIT 3.1 tv479351_ex3-1.htm EX-3.1 17186
3 EXHIBIT 3.2 tv479351_ex3-2.htm EX-3.2 21127
4 GRAPHIC image_002.gif GRAPHIC 84
5 GRAPHIC image_002.jpg GRAPHIC 3296
6 GRAPHIC image_026.jpg GRAPHIC 4997
  Complete submission text file 0001144204-17-058420.txt   78449
Mailing Address 1311 PINEVIEW DRIVE SUITE 501 MORGANTOWN WV 26505
Business Address 1311 PINEVIEW DRIVE SUITE 501 MORGANTOWN WV 26505 304 292-2226
Protea Biosciences Group, Inc. (Filer) CIK: 0001335103 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-51474 | Film No.: 171196711
SIC: 2834 Pharmaceutical Preparations